| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4930309 | European Neuropsychopharmacology | 2017 | 15 Pages |
Abstract
Taken together, the results show that enhancing endocannabinoid signaling in the amygdala and hippocampus produced a more favorable spectrum of effects than those caused by the CRFr1 antagonist. The findings suggest that FAAH inhibitors may be used as a novel treatment for stress-related anxiety disorders.
Related Topics
Life Sciences
Neuroscience
Biological Psychiatry
Authors
Nurit Aisenberg, Lidia Serova, Esther L. Sabban, Irit Akirav,